Stryker Corporation $SYK Shares Bought by Addison Advisors LLC

Addison Advisors LLC grew its holdings in shares of Stryker Corporation (NYSE:SYK) by 8.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,179 shares of the medical technology company’s stock after buying an additional 326 shares during the quarter. Addison Advisors LLC’s holdings in Stryker were worth $1,653,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in SYK. Mid American Wealth Advisory Group Inc. bought a new position in Stryker during the 2nd quarter valued at $26,000. Sachetta LLC increased its position in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the last quarter. Ridgewood Investments LLC raised its stake in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares in the last quarter. Ransom Advisory Ltd bought a new position in shares of Stryker during the first quarter worth about $37,000. Finally, Solstein Capital LLC acquired a new position in Stryker in the second quarter worth about $43,000. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $355.74 on Monday. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a fifty day moving average price of $374.63 and a 200 day moving average price of $381.38. The company has a market cap of $136.04 billion, a P/E ratio of 47.12, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SYK. Rothschild & Co Redburn began coverage on Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. Truist Financial reiterated a “hold” rating and issued a $392.00 price target (down from $407.00) on shares of Stryker in a report on Monday, November 3rd. UBS Group set a $408.00 price target on Stryker in a research report on Monday, October 13th. Rothschild Redb raised shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Finally, Needham & Company LLC increased their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $433.37.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 520,500 shares of company stock valued at $184,803,065 over the last three months. 5.90% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.